Humana Inc. (NYSE:HUM) Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. raised its position in shares of Humana Inc. (NYSE:HUM) by 58.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,579 shares of the insurance provider’s stock after purchasing an additional 5,750 shares during the period. Pacer Advisors Inc.’s holdings in Humana were worth $3,953,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. International Assets Investment Management LLC grew its holdings in Humana by 261,025.1% in the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after buying an additional 738,701 shares in the last quarter. FMR LLC increased its holdings in shares of Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after purchasing an additional 643,291 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Humana by 55.6% during the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock valued at $190,145,000 after purchasing an additional 214,535 shares in the last quarter. Pzena Investment Management LLC lifted its holdings in Humana by 8.1% in the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after purchasing an additional 187,903 shares during the period. Finally, Worldquant Millennium Advisors LLC bought a new position in Humana in the 3rd quarter valued at about $50,102,000. Institutional investors own 92.38% of the company’s stock.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.32% of the stock is owned by company insiders.

Humana Stock Performance

Shares of HUM stock opened at $296.88 on Friday. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The stock’s 50-day moving average is $275.44 and its two-hundred day moving average is $303.07. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market cap of $35.75 billion, a P/E ratio of 26.30, a PEG ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Analysts predict that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

HUM has been the topic of a number of recent analyst reports. Jefferies Financial Group downgraded shares of Humana from a “buy” rating to a “hold” rating and dropped their price target for the stock from $519.00 to $253.00 in a research report on Monday, October 7th. UBS Group cut their target price on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, October 4th. Wells Fargo & Company lowered their price target on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Barclays upped their price objective on Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, January 22nd. Finally, Stephens reissued an “equal weight” rating and issued a $250.00 price target on shares of Humana in a report on Wednesday, October 9th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus price target of $297.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.